The MHRA has released guidance saying that Chloroquine and Hydroxychloroquine are not licensed for coronavirus treatment.
Recent media reports have suggested that chloroquine can protect patients from coronavirus or treat COVID-19, the illness caused by a coronavirus.
In a statement the Medicines and Healthcare products Regulatory Agency (MHRA) said: “We understand these are challenging times, and patients may be worried, but we are doing everything we can to continue to ensure patient safety.
“Chloroquine and hydroxychloroquine are not licensed to treat COVID-19 related symptoms or prevent infection.
“Clinical trials are ongoing to test chloroquine and hydroxychloroquine as an agent in the treatment of COVID-19 or to prevent COVID-19 infection. These clinical trials are still not completed, so no conclusions have been reached on the safety and effectiveness of this medicine to treat or prevent COVID-19.
“Until we have clear, definitive evidence these treatments are safe and effective for the treatment of COVID-19, they should only be used for this purpose within a clinical trial.”
The guidance that Chloroquine and Hydroxychloroquine is not licensed for coronavirus treatment is part of the MHRA’s ongoing guidance on coronavirus (COVID-19).
The MHRA is working closely with Department of Health and Social Care and other healthcare partners on COVID-19.
They are prioritising work including:
- Supporting and authorising the development of vaccines
- Clinical trials of new medicines
- Managing the supply of medicines and healthcare products.